Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $114.6 million.

  • Fortress Biotech's Total Non-Current Liabilities fell 1699.43% to $114.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year decrease of 1699.43%. This contributed to the annual value of $144.1 million for FY2024, which is 1215.21% down from last year.
  • As of Q3 2025, Fortress Biotech's Total Non-Current Liabilities stood at $114.6 million, which was down 1699.43% from $120.8 million recorded in Q2 2025.
  • Fortress Biotech's Total Non-Current Liabilities' 5-year high stood at $242.4 million during Q4 2022, with a 5-year trough of $114.6 million in Q3 2025.
  • Over the past 5 years, Fortress Biotech's median Total Non-Current Liabilities value was $165.6 million (recorded in 2021), while the average stood at $174.2 million.
  • Per our database at Business Quant, Fortress Biotech's Total Non-Current Liabilities skyrocketed by 7125.59% in 2021 and then crashed by 3233.24% in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's Total Non-Current Liabilities stood at $168.6 million in 2021, then surged by 43.8% to $242.4 million in 2022, then plummeted by 32.33% to $164.0 million in 2023, then fell by 12.15% to $144.1 million in 2024, then dropped by 20.47% to $114.6 million in 2025.
  • Its last three reported values are $114.6 million in Q3 2025, $120.8 million for Q2 2025, and $143.9 million during Q1 2025.